← brief for 2026-08-12 · Slowing decline

NephJC Short: 24-Month Iptacopan eGFR Data in IgA Nephropathy — NephJC

Page A Not peer reviewed Meta-analysis or large trial

Key takeaways

This is a journal club covering 24-month results for iptacopan, a drug for IgA nephropathy, a common kidney disease. It comes from APPLAUSE-IgAN, a large late-stage randomized trial, and shows the drug helped protect the kidney filtering rate (eGFR) over two years. This is a blog summary, but the underlying trial is strong evidence. Longer-term data like this suggests a real benefit for slowing kidney decline.

Source

Page · Forager · 2026-08-13
https://www.nephjc.com/news/2026/short/iptacopanegfr24month